Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections

Trial Profile

A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exeporfinium chloride (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Therapeutic Use
  • Sponsors Destiny Pharma
  • Most Recent Events

    • 23 Sep 2019 According to a Destiny Pharma media release, Interim safety, efficacy and futility analysis of the trial, performed by independent safety monitoring board, is planned for end of 2019.
    • 23 Sep 2019 According to a Destiny Pharma media release, the enrollment in European site set-up is on schedule but US sites are recruiting slower than expected. Consequently, recruitment is expected to complete in early 2020 with results announced later in mid-2020.
    • 31 Jul 2019 According to an Destiny Pharma media release, the clinical potential of XF-73, in the prevention of post-operative Staphylococcal infections will be presented at the prestigious Gordon Research Conference (GRC) on staphylococcal diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top